{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:06:50Z","timestamp":1788912410453,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["REF: TTK240315209308"],"award-info":[{"award-number":["REF: TTK240315209308"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"crossref","award":["EDCTP Grant number: RIA2017S"],"award-info":[{"award-number":["EDCTP Grant number: RIA2017S"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57511-4","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:08:18Z","timestamp":1781881698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cervicovaginal microbiome diversity was not associated with mucosal pharmacokinetics of systemically delivered HIV broadly neutralizing antibodies"],"prefix":"10.1038","volume":"16","author":[{"given":"Andile","family":"Mtshali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou Hamidou","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asavela","family":"Kama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marothi","family":"Letsoalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gugulethu","family":"Mzobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Sivro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomusa","family":"Zondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharana","family":"Mahomed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derseree","family":"Archary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinaye","family":"Ngcapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"57511_CR1","unstructured":"UNAIDS. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. (Accessed 17 Sept 2025) (2025)."},{"issue":"7","key":"57511_CR2","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2352-3018(24)00098-5","volume":"11","author":"C Beyrer","year":"2024","unstructured":"Beyrer, C. et al. Is HIV epidemic control by 2030 realistic? Lancet HIV. 11(7), e489\u2013e494 (2024).","journal-title":"Lancet HIV"},{"issue":"1","key":"57511_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-med-110118-045506","volume":"71","author":"ST Karuna","year":"2020","unstructured":"Karuna, S. T. & Corey, L. Broadly neutralizing antibodies for HIV prevention. Annu. Rev. Med. 71(1), 329\u2013346 (2020).","journal-title":"Annu. Rev. Med."},{"key":"57511_CR4","doi-asserted-by":"publisher","first-page":"712122","DOI":"10.3389\/fimmu.2021.712122","volume":"12","author":"SR Walsh","year":"2021","unstructured":"Walsh, S. R. & Seaman, M. S. Broadly neutralizing antibodies for HIV-1 prevention. Front. Immunol. 12, 712122 (2021).","journal-title":"Front. Immunol."},{"issue":"8","key":"57511_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/nm.1974","volume":"15","author":"AJ Hessell","year":"2009","unstructured":"Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15(8), 951\u2013954 (2009).","journal-title":"Nat. Med."},{"issue":"5","key":"57511_CR6","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","volume":"73","author":"JR Mascola","year":"1999","unstructured":"Mascola, J. R. et al. Protection of macaques against pathogenic simian\/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies. J. Virol. 73(5), 4009\u20134018 (1999).","journal-title":"J. Virol."},{"issue":"21","key":"57511_CR7","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88(21), 12669\u201312682 (2014).","journal-title":"J. Virol."},{"issue":"4","key":"57511_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jiz532","volume":"222","author":"CK Cunningham","year":"2020","unstructured":"Cunningham, C. K. et al. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. J. Infect. Dis. 222(4), 628\u2013636 (2020).","journal-title":"J. Infect. Dis."},{"issue":"10","key":"57511_CR9","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","volume":"6","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 6(10), e667\u2013e679 (2019).","journal-title":"Lancet HIV"},{"issue":"4","key":"57511_CR10","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","volume":"10","author":"S Mahomed","year":"2023","unstructured":"Mahomed, S. et al. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Lancet HIV. 10(4), e230\u2013e243 (2023).","journal-title":"Lancet HIV"},{"issue":"16","key":"57511_CR11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1097\/QAD.0000000000000432","volume":"23","author":"A Buve","year":"2014","unstructured":"Buve, A., Jespers, V., Crucitti, T. & Fichorova, R. N. The vaginal microbiota and susceptibility to HIV. AIDS. 23(16), 2333\u20132344 (2014).","journal-title":"AIDS"},{"issue":"Suppl 4","key":"57511_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/01.aids.0000390704.35642.47","volume":"24","author":"R Hayes","year":"2010","unstructured":"Hayes, R., Watson-Jones, D., Celum, C., van de Wijgert, J. & Wasserheit, J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS 24(Suppl 4), S15\u201326. https:\/\/doi.org\/10.1097\/01.aids.0000390704.35642.47 (2010).","journal-title":"AIDS"},{"key":"57511_CR13","doi-asserted-by":"publisher","unstructured":"Anahtar, M. N. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 42(5), 965\u2013976. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.019 (2015).","DOI":"10.1016\/j.immuni.2015.04.019"},{"key":"57511_CR14","doi-asserted-by":"publisher","unstructured":"Mtshali, A. et al. Temporal changes in vaginal microbiota and genital tract cytokines among South African women treated for bacterial vaginosis. Front. Immunol. 12(3756). https:\/\/doi.org\/10.3389\/fimmu.2021.730986 (2021).","DOI":"10.3389\/fimmu.2021.730986"},{"issue":"11","key":"57511_CR15","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1089\/aid.2015.0006","volume":"31","author":"AR Thurman","year":"2015","unstructured":"Thurman, A. R. et al. Bacterial vaginosis and subclinical markers of genital tract inflammation and mucosal immunity. AIDS Res. Hum. Retroviruses. 31(11), 1139\u20131152. https:\/\/doi.org\/10.1089\/aid.2015.0006 (2015).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"6341","key":"57511_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.aai9383","volume":"02","author":"NR Klatt","year":"2017","unstructured":"Klatt, N. R. et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science. 02(6341), 938\u2013945. https:\/\/doi.org\/10.1126\/science.aai9383 (2017).","journal-title":"Science"},{"key":"57511_CR17","unstructured":"Hillier, S. L. et al. Impact of vaginal microbiota on genital tissue and plasma concentrations of tenofovir 2017."},{"issue":"13","key":"57511_CR18","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/QAD.0b013e32833c323b","volume":"24","author":"CR Cohen","year":"2010","unstructured":"Cohen, C. R. et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. Aids. 24(13), 2069\u20132074. https:\/\/doi.org\/10.1097\/QAD.0b013e32833c323b (2010).","journal-title":"Aids"},{"key":"57511_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jri.2016.11.008","volume":"119","author":"AK Boyle","year":"2017","unstructured":"Boyle, A. K., Rinaldi, S. F., Norman, J. E. & Stock, S. J. Preterm birth: Inflammation, fetal injury and treatment strategies. J. Reprod.Immunol. 119, 62\u201366. https:\/\/doi.org\/10.1016\/j.jri.2016.11.008 (2017).","journal-title":"J. Reprod.Immunol."},{"issue":"7","key":"57511_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods. 13(7), 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"issue":"4","key":"57511_CR21","doi-asserted-by":"publisher","first-page":"e61217","DOI":"10.1371\/journal.pone.0061217","volume":"8","author":"PJ McMurdie","year":"2013","unstructured":"McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE. 8(4), e61217 (2013).","journal-title":"PLoS ONE"},{"key":"57511_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-020-00934-6","volume":"8","author":"MT France","year":"2020","unstructured":"France, M. T. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 8, 1\u201315 (2020).","journal-title":"Microbiome"},{"issue":"1","key":"57511_CR23","first-page":"51","volume":"445","author":"W McKinney","year":"2010","unstructured":"McKinney, W. Data structures for statistical computing in Python. SciPy 445(1), 51\u201356 (2010).","journal-title":"SciPy"},{"issue":"11","key":"57511_CR24","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1080\/STA-200066418","volume":"34","author":"JC Yue","year":"2005","unstructured":"Yue, J. C. & Clayton, M. K. A similarity measure based on species proportions. Commun. Statistics-theory Methods. 34(11), 2123\u20132131 (2005).","journal-title":"Commun. Statistics-theory Methods"},{"issue":"6","key":"57511_CR25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/trf.12501","volume":"54","author":"I Martinez-Saguer","year":"2014","unstructured":"Martinez-Saguer, I. et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 54(6), 1552\u20131561. https:\/\/doi.org\/10.1111\/trf.12501 (2014).","journal-title":"Transfusion"},{"issue":"3","key":"57511_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12248-024-00930-w","volume":"10","author":"J Felderman","year":"2024","unstructured":"Felderman, J., Ramaiah, L., Vazquez-Abad, M. D., Messing, D. & Chen, Y. Anti-drug antibody incidence comparison of therapeutic proteins administered via subcutaneous vs. intravenous route. American Association Pharm. Scientists. 10(3), 60. https:\/\/doi.org\/10.1208\/s12248-024-00930-w (2024).","journal-title":"American Association Pharm. Scientists"},{"issue":"1","key":"57511_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","volume":"22","author":"P Tebas","year":"2025","unstructured":"Tebas, P. Future of bNAbs in HIV treatment. Curr. HIV\/AIDS. Rep. 22(1), 34 (2025).","journal-title":"Curr. HIV\/AIDS. Rep."},{"issue":"8","key":"57511_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1136\/sextrans-2014-051601","volume":"90","author":"L Masson","year":"2014","unstructured":"Masson, L. et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sexually transmitted infections 90(8), 580\u2013587. https:\/\/doi.org\/10.1136\/sextrans-2014-051601 (2014).","journal-title":"Sexually Transm. Infect."},{"issue":"1","key":"57511_CR29","doi-asserted-by":"publisher","first-page":"16187","DOI":"10.1038\/s41598-022-20486-z","volume":"28","author":"N Mazibuko-Motau","year":"2022","unstructured":"Mazibuko-Motau, N. et al. Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women. Sci. Rep. 28(1), 16187. https:\/\/doi.org\/10.1038\/s41598-022-20486-z (2022).","journal-title":"Sci. Rep."},{"issue":"10","key":"57511_CR30","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/s2352-3018(17)30110-8","volume":"4","author":"R Heffron","year":"2017","unstructured":"Heffron, R. et al. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV. 4(10), e449\u2013e456. https:\/\/doi.org\/10.1016\/s2352-3018(17)30110-8 (2017).","journal-title":"Lancet HIV"},{"issue":"4","key":"57511_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nm.4506","volume":"24","author":"LR McKinnon","year":"2018","unstructured":"McKinnon, L. R. et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat. Med. 24(4), 491\u2013496. https:\/\/doi.org\/10.1038\/nm.4506 (2018).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57511-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57511-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57511-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:17:05Z","timestamp":1788909425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57511-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57511"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57511-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC00000857\/2019 and the South African Health Products Regulatory Authority (SAHPRA 20200123).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28167"}}